Mc-MMAE

Mc-MMAE (Maleimidocaproyl-monomethylauristatin E) is a drug-linker conjugate for ADC. Mc-MMAE is a maleimidocaproyl-conjugated monomethyl auristatin E, which is a potent tubulin inhibitor.

Cys-mc-MMAE, a Drug-Linker Conjugate for ADC, comprises Monomethyl auristatin E coupled with a linker. It is utilized in the synthesis of ADCs [1].

Mc-Pro-PAB-MMAE is an ADC (antibody-drug conjugate) drug-linker conjugate composed of Monomethylauristatin E and a linker. This compound is utilized in the synthesis of ADCs (antibody-drug conjugates).

MC-Val-Lys(mPEG23)-PAB-MMAE is a part of the antibody-conjugated active molecule ADC, featuring degradable and hydrophilic modification characteristics, and can be used for the synthesis of ADC compounds.

Cys-MC-VC-PAB-MMAE is an antibody-drug conjugate metabolite used for the synthesis of antibody-drug conjugates (ADCs).

MC-betaglucuronide-MMAE-1 is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), utilizing MMAE (a tubulin polymerization inhibitor) connected via the cleavable ADC linker MC-betaglucuronide.

MC-VA-PABC-MMAE is a conjugate composed of the ADC linker peptide MC-VA-PABC and the cytotoxic agent monomethyl auristatin E (MMAE), a potent inhibitor of tubulin polymerization [1] [2]. It functions as an agent-linker module for antibody-drug conjugates (ADCs).

GGGDTDTC-Mc-vc-PAB-MMAE is a drug-linker conjugate for antibody-drug conjugates (ADCs), containing monomethyl auristatin E (MMAE), a tubulin inhibitor, as the cytotoxic component [1].

MC-EVCit-PAB-MMAE (Linker-Payload 11), a conjugate used in antibody-drug conjugates (ADCs), consists of the MC-EVCit-PAB linker connected to the potent tubulin polymerization inhibitor MMAE [1].

MC-betaglucuronide-MMAE-2 is an ADC (antibody-drug conjugate) agent-linker conjugate that exhibits potent antitumor activity; it consists of MMAE (a tubulin polymerization inhibitor) connected through the cleavable linker MC-betaglucuronide.

Compound 2, Mc-Phe-Lys-PAB-MMAE, serves as a drug-linker conjugate for antibody-drug conjugates (ADCs) and is utilized in the synthesis of ADCs [1].

Mc-Val-Cit-PAB-Cl, a cleavable ADC linker, is utilized in the conjugation of MMAE and antibodies to produce compounds such as antibody-MC-vc-MMAE (e.g., anti-CD22-MC-VC-PABC-MMAE), which demonstrate cytotoxicity with IC50s of 3.3 and 0.95 nM against BJAB and WSU cell lines, respectively.

VCMMAE (mc-vc-PAB-MMAE) is a drug-linker conjugate for ADC with potent antitumor activity.